Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.44 - A Difficult to Treat Chronic Urticaria With Psychological Stress, High Anti-Thyroglobulin and De-labeling Hypersensitivity Reaction to Cetirizine
D1.45 - Omalizumab Reduces Anaphylactic Reactions and Facilitates Food Introduction in Food-Allergic Children with Severe Asthma: A Case Report
D1.48 - Challenging decisions: Feasibility and safety of multiple low-risk drug challenges in a single clinic visit during peri-operative anaphylaxis investigation
D1.49 - Crossed-reactivity among Proton Pump Inhibitors in Immediate Severe Hipersensitivity Reactions
D1.50 - Coconut Oil Anaphylaxis after Mucous Exposure, in a Patient with Primary Coconut Allergy
D1.53 - Anaphylaxis to Beta-Lactams: The Importance of the Oral Challenge Test in Diagnosis
D1.54 - Nut Allergy in the Spotlight: The Crucial Role of Oral Provocation Tests
D1.55 - Assembling the Idiopathic Anaphylaxis Puzzle: Where was the secret key for Idiopathic anaphylaxis’s box?
D1.46 - Allergic Reaction to Quadrivalent Meningococcal Conjugate Vaccine (MCV4): Case Report and Diagnostic Approach
D1.435 - Eosinophilic diseases: from nasal polyposis, eosinophilic asthma to EGPA (Eosinophilic Vasculitis with PolyAngioitis), evaluation of possible biomarkers of disease evolution
D1.437 - Frequency of SNPs associated with pharmacogenetic phenotypes in Asthma in two Colombian populations
D1.439 - Is allergic conjunctivitis tip of the allergic iceberg ?
D1.440 - Single cell pipeline to improve immune cell annotation through comparison of multiple bioinformatic methods
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download